Conclusions
- PAK1/PAK2/PAK3 fusion events are found in borderline/low-grade and high-grade serous tumors of the ovary, fallopian tube, and peritoneum and feature a diversity of gene partners.
- Despite their rarity, they may in the future have important treatment implications with the emergence of new targeted therapies.

